
1 INTRODUCTION	page
1.1 Human Hepatitis B virus (HBV)	1
1.1.1 Pathogenesis of Hepatitis B	1
1.1.2 Genome organization of HBV	3
1.1.3 Structure of HBV virion	5
1.1.4 HBV life cycle	5
1.1.5 Experimental models for the study and therapy of HBV infection	7
1.2 Cytokines as mediator immune modulation and antiviral responses	9
1.2.1 Large family of interferons	9
1.2.1.1 Type I interferon	10
1.2.1.2 Type II interferon	11
1.2.2 Induction of interferon expression	12
1.2.3 Interferon-inducible intracellular mechanisms as antiviral response	13
1.3 Adenovirus as vector for gene transfer	14
1.3.1 Pathogenesis of adenoviral infection	14
1.3.2 Structure and genome organization of Adenovirus	14
1.3.3 Adenovirus life cycle	16
1.3.4 Recombinant Adenovirus type 5 as vector for gene transfer	17
1.4 Tetracycline-based inducible system: the Tet-off and Tet-on system	18
1.5 Aims of study	19
2 RESULTS	21
2.1 Suppression of HBV replication following cytokine gene transfer	21
2.1.1 Expression and Secretion of cytokine following adenoviral transduction	22
2.1.1.1 Detection of secretion of mIFN γ using mIFN γ -specific ELISA	22
2.1.1.2 Indirect detection of secretion of mIFN α and mIFN β by induction of 2',5'-oligoadenylate synthetase (2'5'OAS) transcription	23
2.1.1.3 Indirect measurement of secretion of interferon by detection of induction of IP10 transcription <i>in vitro</i> and <i>in vivo</i> .	24
2.1.2 Characterization of antiviral effect of cytokine expression on HBV replication in transduced mouse hepatocytes line	27
2.1.3 Characterization of the antiviral effect of cytokine expression on HBV replication in HBV transgenic mice	31
2.1.3.1 Antiviral effect on HBV replication dependent on the dose of the adenoviral vector	32

	page
2.1.3.2 Kinetics of an antiviral effect on HBV replication	35
2.1.3.3 Time course of constitutive expression of cytokine <i>in vivo</i>	38
2.2 Effect on HBV replication following gene transfer for tet-regulatable and liver specific cytokine expression	40
2.2.1 Establishment of a system allowing regulatable, liver specific gene expression using adenoviral vectors	40
2.2.1.1 Establishment of the Adbiluc system <i>in vitro</i>	42
2.2.1.1.1 Basal expression of luciferase by Adbiluc in primary human hepatocytes	43
2.2.1.1.2 Gene expression in hepatoma HuH7 cells expressing the reverse tet-transactivator	44
2.2.1.1.3 Adenovirus mediated rtTA expression	46
2.2.1.1.4 Tet-inducible luciferase expression using an one-component vector system	48
2.2.1.2 Establishment of the Adbiluc system <i>in vivo</i>	49
2.2.1.2.1 Induction of luciferase expression in the liver of tTA transgenic mice	49
2.2.1.2.2 Kinetics of luciferase activity in living tTA or rtTA transgenic mice	51
2.2.1.2.3 Co-expression of two marker genes in liver cells	53
2.2.1.2.4 Time course of cytokine and luciferase expression following gene transfer in rtTA transgenic mice	55
2.2.2 Antiviral effect of tet-inducible cytokine gene transfer on HBV replication in HBV transgenic mice, a model for chronic infection.	57
2.2.2.1 H1.3/rtTA double transgenic mouse as model for chronic infection	57
2.2.2.2 Effect on HBV replication in TetH1.3 transgenic mice	57
2.2.3 Tet-inducible cytokine expression in rtTA transgenic mice infected with AdGH1.3, a model for acute HBV infection.	61
3 DISCUSSION	64
3.1 Establishment of experimental mouse models	64
3.1.1 <i>In vitro</i> and <i>in vivo</i> models for HBV replication	64
3.1.2 Efficiency of adenoviral-mediated gene transfer into the liver of mice	67

	page
3.2 A liver specific tetracycline-regulated gene expression via adenoviral gene transfer in mice	69
3.3 Novel option to study hepatitis B virus infection	73
3.3.1 Is the cytokine expression a good strategy for antiviral approach on HBV infection ?	73
3.3.2 Antiviral effects of each cytokine on HBV replication	75
3.3.3 Immune response to the adenoviral vector <i>in vivo</i>	82
3.4 Futures perspectives	83
4 MATERIALS and METHODS	85
4.1 Material	85
4.1.1 Instruments	85
4.1.2 Important chemicals, solutions and buffers	85
4.1.3 Molecular weight markers	88
4.1.4 Cell types and characteristics	89
4.1.5 Bacteria strains	89
4.1.6 Mice types	90
4.1.7 Antibodies	90
4.1.8 Oligonucleotids	90
4.1.9 DNA probes	91
4.2 Methods	91
4.2.1 Methods for molecular analysis	91
4.2.1.1 Quick plasmid DNA mini-preparation	91
4.2.1.2 Preparation of large amounts of plasmid DNA	92
4.2.1.3 Ethanol and Isopropanol DNA precipitation	92
4.2.1.4 Cleavage of DNA using restriction enzymes	92
4.2.1.5 Quick isolation or purification of DNA-fragments	92
4.2.1.6 Remove the 5'end phosphate of DNA-fragment by alkaline phosphatase	93
4.2.1.7 The polymerase chain reaction (PCR)	93
4.2.1.8 Real-time PCR by Light Cycler	93
4.2.1.9 Ligation of DNA fragments into vectors	95
4.2.1.10 Generation of blunt ends in digested plasmid	95

	page
4.2.1.11 Rubidium Chloride method for preparing transformation competent <i>E. coli</i>	95
4.2.1.12 Bacteria transformation by heath stock	95
4.2.1.13 Production of transformation electro-competent bacteria	96
4.2.1.14 Transformation of electro-competent bacteria	96
4.2.2 Biological methods	96
4.2.2.1 Cytotoxicity staining assay by crystal violet staining	96
4.2.2.2 <i>In vivo</i> monitoring of luciferase activity	97
4.2.2.3 Preparation of avertin narcose solution	97
4.2.2.4 Calcium phosphate transfection of plasmid in cell culture	98
4.2.3 Methods for biochemical analysis	98
4.2.3.1 Electrophoretic separation of DNA on agarose gel	98
4.2.3.2 DNA extraction with cell lysate or tissue by phenol/chloroform extraction	98
4.2.3.3 DNA extraction with tail of transgenic mouse for PCR screening	98
4.2.3.4 DNA extraction from blood or serum of mouse for real-time PCR	99
4.2.3.5 Preparation of nuclease-free water	99
4.2.3.6 Extraction of total RNA from cell lysate or tissue by TRIZOL [®] LS methods	99
4.2.3.7 Extraction of mRNA from total RNA by Oligotex [™] kit	100
4.2.3.8 Western Blot analysis	100
4.2.3.9 Southern Blot analysis	101
4.2.3.10 Dot Blot analysis	102
4.2.3.11 Northern Blot analysis	102
4.2.3.12 Luciferase activity assay	103
4.2.3.13 Protein determination of Bradford methods	103
4.2.3.14 Murine IFN γ specific ELISA	104
4.2.3.15 HBsAg and HBeAg specific ELISA	104
4.2.3.16 Titration of alanine transaminase (ALT)	104
4.2.4 Cell culture	105
4.2.4.1 Cell culture medium	105
4.2.4.2 Passage of cells	105
4.2.4.3 Infection of cells with adenovirus	105
4.2.4.4 Preparation of primary mouse hepatocytes	106
4.2.6 Adenovirus generation and production	107
4.2.6.1 Constructing recombinant Shuttle plasmid	107
4.2.6.2 Generation of recombinant adenoviral DNA	107
4.2.6.3 Production recombinant Adenovirus	108
4.2.6.4 Production of high titer recombinant Adenovirus stocks	110

	page
4.2.6.5 Titration of adenovirus stocks by GFP expression and/or cytopathic effect	110
4.2.6.6 Titration of adenovirus stocks by immunofluorescence staining	110
4.2.6.7 Titration of adenovirus stocks by OD measure at 260nm reading	111
4.3 Cloning and generation of adenoviral vectors	111
4.3.1 AdShuttle	111
4.3.2 AdmIFN γ or AdvIL10	111
4.3.3 AdGmIFN β	112
4.3.4 AdGFP	112
4.3.5 AdTTR-rtTA	112
4.3.6 Adbiluc and Adbiluc2	112
4.3.7 Adbiluc-GFP	113
4.3.8 Adbiluc-mIFN γ	114
4.3.9 Adbiluc-mIFN α	114
4.3.10 Adbiluc-mIFN β	114
4.3.11 Adbiluc-rtTA and Adbiluc2-rtTA	115
5 SUMMARY	116
6 APPENDIX	118
6.1 Abbreviations	118
6.2 References	120
6.3 Curriculum vitae	137
6.4 Acknowledgement	140